Thrombosis of Medium-Sized and Large Arteries During Covid-19 Infection: Results of the COVIVASC Study.
Journal
Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
01
2022
revised:
15
03
2022
accepted:
15
04
2022
pubmed:
6
7
2022
medline:
15
11
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
COVID-19 infection is associated not only with venous thromboses but also with arterial thromboses (COV-ATs) in relation with an endothelial dysfunction, a coagulopathy and rhythm disorders. The incidence, the topography, and the prognosis of COV-ATs remain poorly known. The objective of this study was to report the overall experience of the Greater Paris University Hospitals (Assistance Publique - Hopitaux de Paris, AP-HP) during the first pandemic wave of COVID-19 infection. After approval by the ethics committee, a study using the AP-HP clinical data warehouse was carried out between March and May 2020. Overall, 124,609 patients had a polymerase chain reaction for COVID-19 in our hospitals, of which 25,345 were positive. From 20,710 exploitable stays, patients tested positive for COVID who presented an episode of acute COV-AT (except coronary and intracranial arteries) were selected on the basis of the French medical classification for clinical procedures codes. The data are presented as absolute values with percentages and/or means with standard deviation. Over the studied period, 60 patients (aged 71±14 years, 42 men) presented a COV-AT at the time of their hospitalization, an incidence of 0.2%. The arterial complication occurred 3±7 days after the COVID infection and was inaugural in 30% of the cases (n = 18). The sites of COV-AT were the lower extremities (n = 35%, 58%), the abdominal aorta (n = 10%, 17%), the thoracic aorta (n = 7%, 12%), the upper limbs (n = 7%, 12%), the cerebral arteries (n = 7%, 12%), the digestive arteries (n = 6%, 10%), the renal arteries (n = 2%, 3%), and the ophthalmic artery (n = 1%, 2%). Multiple COV-ATs were observed in 13 patients (22%). At the time of diagnosis, 20 (33%) patients were in intensive care, including six (10%) patients who were intubated. On computed tomography angiography, COVID lesions were classified as moderate and severe in 25 (42%) and 21 (35%) cases, respectively. Revascularization was attempted in 27 patients (45%), by open surgery in 16 cases, using endovascular techniques in 8 cases and with a hybrid approach in three cases. Six patients (22%) required reinterventions. The duration of hospitalization was 12±9 days. Early mortality (in-hospital or at 30 days) was 30% (n = 18). Nine (15%) patients presented severe nonlethal ischemic complications. Arterial involvement is rare during COVID-19 infection. The aorta and the arteries of the limbs are the privileged sites. The morbi-mortality of these patients is high. Future studies will have to determine if the systematization of anticoagulation therapy decreases the incidence and the severity of the condition.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 infection is associated not only with venous thromboses but also with arterial thromboses (COV-ATs) in relation with an endothelial dysfunction, a coagulopathy and rhythm disorders. The incidence, the topography, and the prognosis of COV-ATs remain poorly known. The objective of this study was to report the overall experience of the Greater Paris University Hospitals (Assistance Publique - Hopitaux de Paris, AP-HP) during the first pandemic wave of COVID-19 infection.
METHODS
METHODS
After approval by the ethics committee, a study using the AP-HP clinical data warehouse was carried out between March and May 2020. Overall, 124,609 patients had a polymerase chain reaction for COVID-19 in our hospitals, of which 25,345 were positive. From 20,710 exploitable stays, patients tested positive for COVID who presented an episode of acute COV-AT (except coronary and intracranial arteries) were selected on the basis of the French medical classification for clinical procedures codes. The data are presented as absolute values with percentages and/or means with standard deviation.
RESULTS
RESULTS
Over the studied period, 60 patients (aged 71±14 years, 42 men) presented a COV-AT at the time of their hospitalization, an incidence of 0.2%. The arterial complication occurred 3±7 days after the COVID infection and was inaugural in 30% of the cases (n = 18). The sites of COV-AT were the lower extremities (n = 35%, 58%), the abdominal aorta (n = 10%, 17%), the thoracic aorta (n = 7%, 12%), the upper limbs (n = 7%, 12%), the cerebral arteries (n = 7%, 12%), the digestive arteries (n = 6%, 10%), the renal arteries (n = 2%, 3%), and the ophthalmic artery (n = 1%, 2%). Multiple COV-ATs were observed in 13 patients (22%). At the time of diagnosis, 20 (33%) patients were in intensive care, including six (10%) patients who were intubated. On computed tomography angiography, COVID lesions were classified as moderate and severe in 25 (42%) and 21 (35%) cases, respectively. Revascularization was attempted in 27 patients (45%), by open surgery in 16 cases, using endovascular techniques in 8 cases and with a hybrid approach in three cases. Six patients (22%) required reinterventions. The duration of hospitalization was 12±9 days. Early mortality (in-hospital or at 30 days) was 30% (n = 18). Nine (15%) patients presented severe nonlethal ischemic complications.
CONCLUSIONS
CONCLUSIONS
Arterial involvement is rare during COVID-19 infection. The aorta and the arteries of the limbs are the privileged sites. The morbi-mortality of these patients is high. Future studies will have to determine if the systematization of anticoagulation therapy decreases the incidence and the severity of the condition.
Identifiants
pubmed: 35780947
pii: S0890-5096(22)00299-0
doi: 10.1016/j.avsg.2022.04.055
pmc: PMC9242891
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-42Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
JAMA. 2020 Dec 22;324(24):2548-2549
pubmed: 33226423
Am J Emerg Med. 2021 Jan;39:213-218
pubmed: 33036855
J Am Heart Assoc. 2021 Feb 2;10(3):e019650
pubmed: 33228447
J Vasc Surg. 2020 Dec;72(6):1864-1872
pubmed: 32360679
Eur J Vasc Endovasc Surg. 2020 Feb;59(2):173-218
pubmed: 31899099
Eur J Vasc Endovasc Surg. 2020 Dec;60(6):827
pubmed: 32800476
Ann Vasc Surg. 2018 Aug;51:106-112
pubmed: 29518503
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Anesthesiology. 2020 May;132(5):1238-1245
pubmed: 32044801
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284
Comput Methods Programs Biomed. 2019 Nov;181:104804
pubmed: 30497872
J Am Heart Assoc. 2021 Apr 20;10(8):e018624
pubmed: 33550816
Rev Mal Respir. 2019 Feb;36(2):249-283
pubmed: 30799126
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75
pubmed: 12588755
Thromb Res. 2020 Aug;192:75-77
pubmed: 32425264
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
Ann Vasc Surg. 2020 Nov;69:317-323
pubmed: 32502677
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Eur J Vasc Endovasc Surg. 2022 Jan;63(1):80-89
pubmed: 34686452
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Vasc Med. 2020 Oct;25(5):471-478
pubmed: 32558620
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2033-2044
pubmed: 32657623
J Clin Med. 2020 Sep 18;9(9):
pubmed: 32962092